How would you like your name to appear on your certificate?

Profession

What activities did you attend at the event?

Friday, November 14 - 1:15 pm - 1:45 pm - Dr. Bass Presentation

Friday, November 14 - 1:45 pm - 2:15 pm - Dr. Terrault Presentation

Friday, November 14 - 2:15 pm - 3:00 pm - Dr. Freise Presentation

Friday, November 14 - 3:30 pm - 4:00 pm - Dr. Yao Presentation

Friday, November 14 - 4:00 pm - 4:30 pm - Dr. Hirose Presentation

Friday, November 14 - 4:30 pm - 5:00 pm - Dr. Stock Presentation

Friday, November 14 - 5:00 pm - 5:30 pm - Dr. Feng Presentation

Friday, November 14 - 5:30 pm - 6:00 pm - Q & A

Saturday, November 15 - 9:00 am - 9:30 pm - Dr. Davern Presentation

Saturday, November 15 - 9:30 am - 10:00 am - Dr. Biggins Presentation

Saturday, November 15 - 10:00 am - 10:30 am - Dr. Fix Presentation

Saturday, November 15 - 10:30 am - 12:00 pm - Case Presentations 1 & 2

Agreement

By completing this form, you attest that you have participated in all selected activities in thier entirety.

I agree

Please rate the following:

Overall quality of the meeting.

The program was relevant to my work.

Content matched stated objectives.

Usefulness of handouts/AV.

Comfort of rooms.

How well did the educational sessions give a balanced view of therapeutic options, including the use of general names?

If you rated any of the above questions with 'fair,' 'poor,' 'disagree,' or 'strongly disagree' please explain:

Please rate the expertise of the speaker - Nathan Bass, MD, PhD.

Please rate the expertise of the speaker - Nora Terrault, MD.

Please rate the expertise of the speaker - Chris Freise, MD.

Please rate the expertise of the speaker - Francis Yao, MD.

Please rate the expertise of the speaker - Peter Stock, MD, PhD.

Please rate the expertise of the speaker - Ryutaro Hirose, MD.

Please rate the expertise of the speaker - Sandy Feng, MD, PhD.

Please rate the expertise of the speakers - Drs. Yao, Bass, Terrault, Freise, Yao, Hirose, Stock and Feng.

Please rate the expertise of the speaker - Timothy Davern, MD.

Please rate the expertise of the speaker - Scott Biggins, MD.

Please rate the expertise of the speaker - Oren Fix, MD, MSCE.

Please rate the expertise of the speaker - Kiran Bambha.

Please rate the expertise of the speaker - Sang-Mo Kang.

Objective 1: Discuss up-to-date information on management of chronic liver disease including hepatitis C, liver cancer, acute liver failure, fatty liver disease and complications of cirrhosis.

The above objective has increased my professional knowledge.

The above objective will increase my professional competence.

The above objective will result in performance changes in my professional practice.

Please rate the teaching ability of the speaker - Nathan Bass, MD, PhD.

Please rate the teaching ability of the speaker - Nora Terrault, MD.

Please rate the teaching ability of the speaker - Chris Freise, MD.

Please rate the teaching ability of the speaker - Francis Yao, MD.

Please rate the teaching ability of the speaker - Peter Stock, MD, PhD.

Please rate the teaching ability of the speaker - Ryutaro Hirose, MD.

Please rate the teaching ability of the speaker - Sandy Feng, MD, PhD.

Please rate the teaching ability of the speakers - Drs. Yao, Bass, Terrault, Freise, Yao, Hirose, Stock and Feng.

Please rate the teaching ability of the speaker - Timothy Davern, MD.

Please rate the teaching ability of the speaker - Scott Biggins, MD.

Please rate the teaching ability of the speaker - Oren Fix, MD, MSCE.

Please rate the teaching ability of the speaker - Kiran Bambha.

Please rate the teaching ability of the speaker - Sang-Mo Kang.

Objective 2: Discuss the care of liver transplant recipients and how it has changed.

The above objective has increased my professional knowledge.

The above objective will increase my professional competence.

The above objective will result in performance changes in my professional practice.

Please rate the speaker's responsiveness to questions:

Please rate the speakers' responsiveness to questions:

Please rate the speaker's responsiveness to questions:

Objective 3: Explain how to manage patients in need of a liver transplantation.

The above objective has increased my professional knowledge.

The above objective will increase my professional competence.

The above objective will result in performance changes in my professional practice.

Discuss the public health impact of the prevalence of nonalcoholic fatty liver disease.

Describe the need and methods in development, for non-invasive diagnosis and staging of NASH.

Discuss the rationale behind current treatment strategies aimed at the prevention of progressive liver disease from NAFLD

Describe the limitations of currently approved HCV therapies and the rationale for new drugs.

List the current antiviral agents in phase 2/3 of drug development and their safety and efficacy.

List risks and benefits of living donor liver transplantation (LDLT), for donor and recipient.

Define the role of LDLT for recipients with HCC.

Discuss the impact of immunosuppression on HIV progression.

Discuss the impact of HIV liver transplant function.

Explain the current concerns regarding the side effects and toxicities of immunosuppression for liver transplantation.

List some novel immunosuppression regimens / drugs and describe the advantages and disadvantages over standard regimens / drugs.

Discuss risk models for endstage liver disease.

Describe current liver allocation system in the US.

Please rate how well the objectives were met.

Discuss diagnosis and management of common complications after liver transplantation.

Describe the evolving epidemiology of ALF in the US.

Compare etiology-specific outcomes of ALF.

Discuss controversial issues surrounding liver transplant "status 1" listing.

Define the role of Sorafenib in the treatment of advanced hepatocellular carcinoma.

Review the use and adverse effects of Sorafenib.

Explain the potential role of Sorafenib as adjuvant therapy in patients who are candidates for liver transplantation.

Identify the diagnostic criteria for portopulmonary hypertension.

Describe why portopulmonary hypertension increases the risk of liver transplantation.

Identify available therapies for portopulmonary hypertension.

Identify and discuss some of the issues and complexities encountered among patients with end-stage liver disease and factors affecting liver transplantation.

Define the potential role of these new antiviral agents in the prevention or treatment of HCV in liver transplant recipients.

Describe the pharmacokinetic interactions between HIV and immunosuppression.

Discuss the current view of spontaneous tolerance among adult and pediatric liver transplant recipients.

If you have additional comments regarding the session or speaker, please use the space below:

If you have additional comments regarding the session or individual speakers, please use the space below:

If you have additional comments regarding the session or speaker, please use the space below:

Please answer the following:

Do you believe this activity was appropriate for the scope of your professional activities?

Do you believe this activity will result in your ability to improve your practice?

Was the educational content scientifically sound?

Was the educational content free of commercial bias?

If faculty spoke about off-label or investigational use of a product, was that information disclosed to you?

Was the mode of education effective to learning?

If you answered 'No' to any of the above questions, please explain:

Were you solicited by sales personnel in an educational room while you attended this educational activity?

If you answered 'Yes' to the above question, please explain:

What did you learn during this activity that you intend to integrate into your practice?

List any perceived practice "gaps" (educational needs/topics) which you would like to see the focus of future trainings.

Are you interested in basic, intermediate or advanced level trainings?

What barriers might you have that would interfere with implementation of new information learned from this training?

How can this training be improved to impact your competence or practice?

Additional comments: